Corvinus
Corvinus

Trading between perceived risks and benefits related to biosimilar biological treatment in Crohn’s disease; discrete choice experiment among gastroenterologists

Baji, Petra and Gulácsi, László and Lovász, Barbara D. and Golovics, Petra A. and Brodszky, Valentin and Péntek, Márta and Rencz, Fanni and Lakatos, Péter L. (2015) Trading between perceived risks and benefits related to biosimilar biological treatment in Crohn’s disease; discrete choice experiment among gastroenterologists. Working Paper. Corvinus University of Budapest Faculty of Economics.

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
990kB

The final version appeared in Scandinavian Journal of Gastroenterology, 2015 Jun 10:1-6. DOI: 10.3109/00365521.2015.1054422

Abstract

Objective: The objective of the study is to explore preferences of gastroenterologists for biosimilar drugs in Crohn’s Disease and reveal trade-offs between the perceived risks and benefits related to biosimilar drugs. Method: Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May, 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator) 2) severity of disease 3) availability of continuous medicine supply 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator 2) willing to consider biosimilar for biological-naïve patients only 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. Results: Men, senior consultants, working in IBD center and treating more patients are more likely to willing to consider biosimilar for biological-naïve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in the case biological-naïve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89% vs 11% for new patients, and 44% vs 56% for patients already treated with biological. Conclusions: Gastroenterologists were willing to trade between perceived risks and benefits of biosimilars. The continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.

Item Type:Monograph (Working Paper)
Series Name:Corvinus Economics Working Papers - CEWP
Series Number / Identification Number:2015/17
Uncontrolled Keywords:risk perception, biologicals, biosimilars, Crohn’s Disease, Discrete Choice Experiment, Preferences
JEL classification:D12 - Consumer Economics: Empirical Analysis
I12 - Health Production
I18 - Health: Government Policy; Regulation; Public Health
Subjects:Social welfare, insurance, health care
Projects:OTKA PD 112499
ID Code:2080
Deposited By: Ádám Hoffmann
Deposited On:01 Oct 2015 10:38
Last Modified:06 Oct 2015 07:13

Repository Staff Only: item control page